The decline that follows small strokes rarely looks like the version families expect. It can arrive overnight, or in steps, a plateau and then a drop, or it can creep in as a slow thickening of thought: slower processing, wandering attention, the planning of a simple meal becoming a project. Those patterns, set out in the companion paper published alongside it, are the clinical face of vascular cognitive impairment and dementia, or VCID, the umbrella term for cognitive loss caused by disease of the brain's blood vessels. What families almost always ask next is what can be done about it. On 6 January 2026, a review in the Journal of the American College of Cardiology tried to answer that honestly, and the honesty is the point.

The paper, written by Louise Goodall of the Garvan Institute of Medical Research in Sydney with Matthew Lennon and Perminder Sachdev of the University of New South Wales, Philip Gorelick of Northwestern University, Jason Kovacic and Katherine Samaras, runs to 24 pages in the journal's first issue of the year (volume 87, pages 77 to 100) and is the second half of a two-part seminar. It is a review, not an experiment: no new patients, no new trial, no new data. Its value is that it collects what is known and orders it, and its opening admission sets the tone. Cardiovascular risk factors contribute to the majority of dementia cases, the authors write, with about 20 percent directly attributable to VCID; yet treatment development here has been slow compared with Alzheimer's disease, which now has several agents approved by the US Food and Drug Administration, some of them aimed at the disease process itself.

On the drugs that already sit in clinic drawers, the review is measured. There is reasonable evidence, the authors judge, that the cognitive enhancers donepezil, galantamine and memantine modestly improve cognition in vascular dementia, the most severe form of VCID, and particularly where Alzheimer's pathology is present alongside the vascular damage, which in later life it very often is. Antidepressants, they report, may help people with depression after stroke, but perform poorly for depression occurring with vascular dementia alone. For the agitation and psychosis that can accompany VCID, they place behavioural, social and environmental approaches first, ahead of medication. None of that is a prescription for any individual reader, and the review does not pretend it is; it is a summary of average findings across populations, and the arithmetic of an average says nothing certain about one person at one kitchen table.

The more interesting spine of the paper is upstream of symptoms, in the biology the field is now aiming at: pressure inside small vessels, the health of the endothelial lining, inflammation, and the metabolic machinery that feeds brain tissue. Of these, blood pressure is the only lever with large randomised evidence behind it, and even that evidence is more modest than the headlines of 2019 suggested. SPRINT, which randomised 9,361 adults aged 50 and over with hypertension but without diabetes or prior stroke to a systolic target below 120 rather than below 140, was stopped early after a median of about 3.3 years of treatment because of benefit on heart outcomes and death. Its cognitive substudy, SPRINT MIND, published in JAMA on 28 January 2019, found fewer cases of mild cognitive impairment in the intensive group, while the reduction in probable dementia on its own did not reach statistical significance. When investigators extended cognitive follow-up and published the longer view in Neurology on 16 January 2025, a median 6.9 years produced 248 cases of probable dementia in the intensive arm (8.5 per 1,000 person-years) against 293 in the standard arm (10.2 per 1,000 person-years). Real, and small, and measured in a hypertension trial that excluded people who had already had a stroke.

That gap between rationale and result is what a family should take from this paper. Endothelial repair, dampened inflammation and metabolic pathways are, at this stage, targets with a logic attached, not treatments with a licence attached. A mechanism that makes elegant sense in a vessel wall has to survive a randomised trial in humans before anyone can say it protects thinking, and the history of dementia research is largely a history of that step failing. What the review offers instead is orientation: a sense of which levers have been tested, which have half-answers, and which are still drawings on a whiteboard. For anyone living with a vascular diagnosis, that is not nothing. It turns a fog into a map, and a map is what you need before you can sensibly ask your own clinician where you are standing on it.